Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Vineet Gupta

Rush University Medical Center, Department: Microbiology/immun/virology

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Adhaere Pharmaceuticals, Inc

Disclosed Value
Listed Reason
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution

Drs Gupta and Reiser are attempting to discover new podocyte directed small molecules as potential therapies for kidney disease. Reiser and Gupta Lab developed a novel HTS (high throughput screening) assay for this project.

Relationship- A patent application has been filed. Reiser/Gupta initiated a patent application in 2013. There are no podocyte cells related to Reiser (no IP on this cell line).

There is an appearance of conflict based on the IP related to the development of assays.

Listed Research Project
Podocyte-based HCS assays for discovering therapeutics against kidney diseases

Chronic kidney disease (CKD) affects over 10% of all adults, and is common in patients with diabetes, hypertension and heart disease. We have limited treatment options available for patients with CKD, which is mostly managed using drugs to for blood pressure. We have recently developed a novel high throughput screening assay that will allow us to identify and develop novel, kidney-directed therapeutics for CKD. We believe that the proposed studies will herald a new generation of therapeutics to treat various kidney diseases.

Filed on May 11, 2016.

Tell us what you know about Vineet Gupta's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Vineet Gupta Rush University Medical Center Conflict of Interest Rush University Medical Center Value cannot be readily determined
Vineet Gupta Rush University Medical Center Conflict of Interest Adhaere Pharmaceuticals, Inc Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page